N-aryl-N'alkyl sulfamides as MEK inhibitors

Details N-aryl-N'alkyl sulfamides as MEK inhibitors N-aryl-N'alkyl sulfamides as MEK inhibitors

2007-04-11

2010-11-30

Havlin, Robert (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C514S709000

Reexamination Certificate

active

07842836

ABSTRACT:
This invention concerns N-(ortho phenylaminoaryl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.

REFERENCES:
patent: 5596008 (1997-01-01), Lee et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 6235764 (2001-05-01), Larson et al.
patent: 6495582 (2002-12-01), Hale et al.
patent: 6511993 (2003-01-01), Dack et al.
patent: 6548526 (2003-04-01), Larson et al.
patent: 6649640 (2003-11-01), Hale et al.
patent: 6989451 (2006-01-01), Zhang et al.
patent: 2003/0149015 (2003-08-01), Barrett et al.
patent: 2004/0029898 (2004-02-01), Boyle et al.
patent: 2004/0039037 (2004-02-01), Zhang et al.
patent: 2004/0152691 (2004-08-01), Lippa et al.
patent: 2005/0143438 (2005-06-01), Wallace et al.
patent: 2007/0244164 (2007-10-01), Yan et al.
patent: 2008/0058340 (2008-03-01), Maderna et al.
patent: 0239362 (1987-09-01), None
patent: 0606046 (1994-07-01), None
patent: 0780386 (1997-06-01), None
patent: 0818442 (1999-01-01), None
patent: 0931788 (1999-08-01), None
patent: 1004578 (2000-05-01), None
patent: 1181017 (2002-02-01), None
patent: WO 90-05719 (1990-05-01), None
patent: WO 96-27583 (1996-09-01), None
patent: WO 96-33172 (1996-10-01), None
patent: WO 98-03516 (1998-01-01), None
patent: WO 98-07697 (1998-02-01), None
patent: WO 98-30566 (1998-07-01), None
patent: WO 98-33768 (1998-08-01), None
patent: WO 98-34915 (1998-08-01), None
patent: WO 98-34918 (1998-08-01), None
patent: WO 99-07675 (1999-02-01), None
patent: WO 99-29667 (1999-06-01), None
patent: WO 99-52889 (1999-10-01), None
patent: WO 99-52910 (1999-10-01), None
patent: WO 03-043985 (2003-05-01), None
Silverman, R. B. (The Org. Chem. of Drug Design and Drug Action, Academic Press, Inc.: San Diego, 1992, pp. 4-51).
Shibata et al. (CAPLUS abstract of WO 2004/083167).
Kubinyi (3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages).
Byrn et al., Pharm. Res., v. 12, n. 7, p. 945-54, 1995.
Khire et al., Bioorganic & Medicinal Chemistry Letters 14 (2004) 783-786.
Zhang et at., Bioorganic & Medicinal Chemistry Letters 10 (2000) 2825-2828.
English and Cobb (Trends in Pharmacological Sciences vol. 23 No. 1 Jan. 2002, p. 40-45).
Berge et al., “Pharmaceutical salts,” J. Pharm. Sci. 66(1): 1-19, 1977.
Buchwald et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis,” Surgery 88(4): 507-16, 1980.
Bundgaard, H. Chapter 5: Design and application of prodrugs. A Textbook of Drug Design and Development. Krosgaard-Larsen, et al., eds., pp. 113-191, 1991.
Bundgaard, H., “Means to enhance penetration: Prodrugs as a means to improve the delivery of peptide drugs,” Advanced Drug Delivery Reviews 8: 1-38, 1992.
Fedorak et al., “A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis,” Am J Physiol 269(2 Pt 1): G210-8, 1995.
Fleisher et al., “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs,” Advanced Drug Delivery Reviews 19(2): 115-30, 1996.
Furniss et al., ed., Vogel's Textbook of Practical Organic Chemistry, 5th Ed. Suppl. (Longman Scientific and Technical Ltd, Essex, UK) pp. 809-816, 1991.
Goodson, J. Dental applications. Medical Applications of Controlled Release, vol. 2, Applications and Evaluations. Langer, et al., eds. (CRC Press, Boca Raton, FL) pp. 115-138, 1984.
Heller, A., “Electrical wiring of redox enzymes,” Acc Chem Res 23(5): 128-34, 1990.
Hochhaus et al. A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids. Biomed Chromatogr. 1992; 6(6): 1992.
Langer, R., “New methods of drug delivery,” Science 249(4976): 1527-33, 1990.
Larsen, et al., “Prodrug forms for the sulfonamide group. I. Evaluation of N-acyl derivative, N-sulfonylamidines, N-sulfonylsulfilimines and sulfonylureas as possible prodrug derivatives,” Int J Pharmaceutics 37(1-2): 87-95, 1987.
Larsen et al., “Prodrug forms for the sulfonamide group. II. Water-soluble amino acid derivatives of N-methylsulfonamides as possible prodrugs,” Int J Pharmaceutics 47(1-3): 103-10, 1988.
McLeod et al., “A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression,” Gastroenterology 106(2): 405-13, 1994.
Robinson et al., “Discovery of the hemifumarate and (alpha-L-alanyloxy)methyl ether as prodrugs of an antirheumatic oxindole: prodrugs for the enolic OH group,” J Med Chem 39(1): 10-8, 1996.
Saudek et al., “A preliminary trial of the programmable implantable medication system for insulin delivery,” N. Engl J Med 321(9): 574-9, 1989.
Saulnier et al., “An efficient method for the synthesis of guanidino prodrugs,” Bioorganic & Medicinal Chemistry Letters 4(16): 1985-90, 1994.
Sefton, M., “Implantable pumps,” Crit Rev Biomed Eng 14(3): 201-40, 1987.
Sinkula et al., “Rationale for design of biologically reversible drug derivatives: prodrugs,” J Pharm Sci 64(2): 181-210, 1975.
Treat et al., “Liposome encapsulated doxorubicin: Preliminary results of phase I and phase II trials,” Liposomes in the Therapy of Infectious Diseases and Cancer. Lopez-Bernstein, et al., eds. (Alan R. Liss, New York) pp. 353-365, 1989.
Varaprasad et al., “Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors,” Bioorg Med Chem Let 16(15):3975-3980, 2006.
Widder et al., ed., Methods in Enzymology (Academic Press, New York) vol. 112, pp. 309-396, 1985.
PCT/US07/66894 Search Report dated Feb. 15, 2008.
STN Abstract of WO 2004083167, Accession # 2004;799553.
PCT/US07/66467 Search Report dated Sep. 29, 2008.

Affiliated with

Also associated with

Rating

N-aryl-N'alkyl sulfamides as MEK inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-aryl-N'alkyl sulfamides as MEK inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-aryl-N'alkyl sulfamides as MEK inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4244047